Cravath’s New York Office Moves to Two Manhattan West
On May 10, 2023, Cravath partner Lauren Angelilli participated in “Tax Planning for Domestic & Foreign Partnerships, LLCs, Joint Ventures & Other Strategic Alliances 2023,” a program presented by the Practising Law Institute from May 9‑11, 2023 in New York. Lauren spoke on a panel entitled “Distressed Partnerships (Including Bankruptcy and CARES Act),” which reviewed the complexities that arise when a distressed borrower is a partnership, including the various types of restructuring transactions that can have varying effects on different partners.
Deals & Cases
February 16, 2023
On February 16, 2023, IFF, an industry leader in food, beverage, scent, health and biosciences, science and creativity, announced it has entered into an agreement to sell its Flavor Specialty Ingredients (“FSI”) business to Exponent, a leading UK‑based private equity firm, for $220 million in cash proceeds. FSI reports through IFF’s Scent division and is a leading manufacturer of synthetic and natural base aroma chemicals used in the flavor market. Cravath is representing IFF in connection with the transaction.
Deals & Cases
October 27, 2022
On October 27, 2022, Altra Industrial Motion Corp. (“Altra”), a premier global manufacturer and supplier of motion control, power transmission and automation products, announced it has entered into a definitive agreement to be acquired by Regal Rexnord Corporation (“Regal Rexnord”) for approximately $5 billion on an enterprise value basis. Cravath is representing Altra in connection with the transaction.
Deals & Cases
October 02, 2022
On October 1, 2022, RWE AG (“RWE”), a leading renewable energy company, signed a purchase agreement with Con Edison, Inc. to acquire all shares in Con Edison Clean Energy Businesses, Inc., a leading operator and developer of renewable energy plants in the United States, for a purchase price based on an enterprise value of $6.8 billion. Cravath is representing RWE, alongside Hengeler Mueller, in connection with the transaction.
Deals & Cases
August 08, 2022
On August 8, 2022, Global Blood Therapeutics, Inc. (“GBT”), a biopharmaceutical company dedicated to the discovery, development and delivery of life‑changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (“Pfizer”) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. Cravath is representing GBT in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.